Long-term effectiveness and safety of the sirolimus-eluting BiOSS LIM® dedicated bifurcation stent in the treatment of distal left main stenosis: an international registry

Abstract

The use of the BiOSS LIM dedicated bifurcation stent for the treatment of distal LM stenosis was feasible and safe, with promising long-term clinical effectiveness.

Assessment of vascular response to BiOSS LIM C® stents vs Orsiro® stents in the porcine coronary artery model

“…It achieved acceptable results both in in vivo studies and in clinical trials. However, clinical results of BiOSS Expert and BiOSS LIM were not very different that was caused mainly by high late lumen loss values in case of BiOSS LIM . Therefore, the idea to reduce the late lumen loss and as a result TLR rate using thinner struts appeared…”

Is it possible to further improve clinical results with coronary bifurcation stenting, or what is more important — the technique or the stent?

“…The device is easy to use, tracked over one wire, with very low profile with a wide range of lengths and diameters, making it applicable in almost all types of coronary bifurcations, including left main distal bifurcation. It is worth mentioning that the results achieved in this last location were even better than for regular bifurcations [54]. The 12-month MACE rate was 9.5% without cardiac death or definite ST. TLR and MI rates were 6.8% (n = 5) and 2.7% (n = 2), respectively.…”

Safety and efficacy of self‐apposing Stentys drug‐eluting stent in left main coronary artery PCI: Multicentre LM‐STENTYS registry

“…Another dedicated bifurcation stent assessed in the setting of LM disease is BiOSS LIM balloon‐expandable stent. In the international registry data presented by Gil et al, 1‐year MACE rate was 9.5%, without cardiac death or definite ST. In that study, low rates of MI and TLR were noted, 2.7 and 6.8%, respectively.…”